These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 20357617)

  • 1. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
    Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
    J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.
    Tabata C; Shibata E; Tabata R; Kanemura S; Mikami K; Nogi Y; Masachika E; Nishizaki T; Nakano T
    BMC Cancer; 2013 Apr; 13():205. PubMed ID: 23617783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
    Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A
    N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?
    Maeda R; Tabata C; Tabata R; Eguchi R; Fujimori Y; Nakano T
    Antioxid Redox Signal; 2011 Aug; 15(3):685-9. PubMed ID: 21375472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
    Hirayama N; Tabata C; Tabata R; Maeda R; Yasumitsu A; Yamada S; Kuribayashi K; Fukuoka K; Nakano T
    Respir Med; 2011 Jan; 105(1):137-42. PubMed ID: 21041073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
    J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.
    Watzka SB; Posch F; Pass HI; Flores RM; Hannigan GE; Bernhard D; Weber M; Mueller MR
    Eur J Cardiothorac Surg; 2013 May; 43(5):940-5. PubMed ID: 23045294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
    Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.
    Kishimoto T; Fujimoto N; Ebara T; Omori T; Oguri T; Niimi A; Yokoyama T; Kato M; Usami I; Nishio M; Yoshikawa K; Tokuyama T; Tamura M; Yokoyama Y; Tsuboi K; Matsuo Y; Xu J; Takahashi S; Abdelgied M; Alexander WT; Alexander DB; Tsuda H
    BMC Cancer; 2019 Dec; 19(1):1204. PubMed ID: 31823764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
    Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
    Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
    Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Canessa PA; Chella A; Lucchi M; Mussi A; Mutti L
    Int J Biol Markers; 2010; 25(3):164-70. PubMed ID: 20878622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation-based prognostic indices in malignant pleural mesothelioma.
    Pinato DJ; Mauri FA; Ramakrishnan R; Wahab L; Lloyd T; Sharma R
    J Thorac Oncol; 2012 Mar; 7(3):587-94. PubMed ID: 22307011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma.
    Tabata C; Kanemura S; Tabata R; Masachika E; Shibata E; Otsuki T; Nishizaki T; Nakano T
    J Clin Gastroenterol; 2013 Sep; 47(8):684-8. PubMed ID: 23685846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma.
    Tabata C; Hirayama N; Tabata R; Yasumitsu A; Yamada S; Murakami A; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Terada T; Nakano T
    Eur Respir J; 2010 Nov; 36(5):1099-105. PubMed ID: 20185425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.